Gonococcal antimicrobial susceptibility surveillance in Europe 2011
This report presents the results from the 2011 gonococcal antimicrobial susceptibility surveillance programme (Euro-GASP) and a summary of the second distribution from the 2011 external quality assurance (EQA) scheme. Twenty one EU/EEA Member States participated in the Euro-GASP programme and nineteen in the EQA scheme.
Effective control of gonorrhoea, the second most commonly reported sexually transmitted infection in Europe, relies on successful antimicrobial treatment. As data from the ECDC report Gonococcal antimicrobial susceptibility surveillance in Europe 2011 illustrate, gonococci have become more resistant to common agents for treatment and show reduced susceptibility to newer antibiotics.
The results show that decreased susceptibility to the previously recommended drug for treatment of gonorrhoea, cefixime, was 7.6% in 2011, a small decline as compared to the 8.7% in 2010. Seventeen countries detected isolates with reduced susceptibility to cefixime including four countries which reported these isolates for the first time. In addition, ten isolates (from two countries) with decreased susceptibility to the currently recommended drug for treatment, ceftriaxone, were detected in Euro-GASP for the first time. As control of gonorrhoea relies on effective antimicrobial treatment, the loss of the currently recommended treatment drugs would have a significant impact on public health: with more than 32 000 reported cases in 2010, gonorrhoea is the second most commonly recorded sexually transmitted infection in Europe.In response to this, ECDC launched a regional response plan to control and manage multidrug-resistant gonorrhoea in 2012 in order to minimise the impact of resistant gonorrhoea in Europe
Influenza virus characterisation, December 2020
18 Jan 2021 - This is the third report for the 2020–2021 influenza season. As of week 53/2020, only 415 influenza detections across the WHO European Region had been reported; 50% type A viruses, with A(H3N2) prevailing over A(H1N1)pdm09, and 50% type B viruses with only four having been ascribed to a lineage, three B/Victoria and one B/Yamagata. This represents a 98% drop in detections compared to the same period in 2019, probably due to the COVID-19 pandemic and measures introduced to combat it.
Congenital toxoplasmosis - Annual Epidemiological Report for 2018
14 Jan 2021 - In 2018, 208 confirmed cases of congenital toxoplasmosis were reported in the EU/EEA, with France accounting for 73% of all confirmed cases due to active screening of pregnant women.
Rabies - Annual Epidemiological Report for 2019
14 Jan 2021 - For 2019, EU/EEA countries reported five human Lyssavirus infections. Four human cases of travel-related rabies were reported by Italy, Latvia, Spain and Norway with exposure in Tanzania, India, Morocco and the Philippines, respectively. One locally-acquired fatal case of European bat lyssavirus (EBLV-1) infection was reported by France.